Compugen Ltd. Stock News

HOLON, Israel , June 12, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the presentation of AI/ML driven predictive computational research at upcoming international scientific conferences reflecting Compugen's scientific capabilities in understanding complex cancer biol...

Compugen Ltd. (NASDAQ:CGEN ) Q1 2025 Earnings Conference Call May 19, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR & Corporate Communications Anat Cohen-Dayag - President & CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Daina Graybosch - Leerink Partners Rohan Mathur - Oppenheimer Asth...

Initiated platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer in Q2 2025 Recruitment ongoing in the first in human Phase 1 trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to Gilead Partner AstraZeneca expanded their rilvegostomig program to ten Phase 3 trials across lung, gastrointestinal and endometrial ...

Anat Cohen-Dayag, Ph.D., appointed as Executive Chair of the Board of Directors Eran Ophir, Ph.D.

HOLON, Israel , May 5, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its first quarter 2025 financial results on Monday, May 19, 2025, before the U.S. financial markets open.

HOLON, Israel , March 26, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming virtual investor conferences in April 2025: H.C.

Compugen Ltd. (NASDAQ:CGEN ) Q4 2024 - Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR and Corporate Communications Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Karina Rabayeva – Truist Securities Daina Graybosch - Leeri...

Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibody On track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025 The first patient was dosed in Q1 2025 in the first in human Phase 1 solid tumor trial of GS-0321 (previo...